9
Additional Mutations in CML
CML AK Book
Preface
1
Introduction
2
TKIs for CML
3
Dasatinib
4
Asciminib
5
ELVN-001
6
TERN-701 CARDINAL Phase 1 Study Analysis
7
TGRX-678 Phase 1 Study Analysis: Efficacy in CML Patients with T315I Mutation
8
Olverembatinib
9
Additional Mutations in CML
10
BCR-ABL1 TKD mutations
11
Guideline Recommendations in CML
12
TKI Discontinuation
13
HSCT for CML
14
Summary
References
9
Additional Mutations in CML
ASXL1 mutation is the driver of TKI resistance
8
Olverembatinib
10
BCR-ABL1 TKD mutations